Table 2 Incidence rates and hazard ratios for mortality and cardiovascular event

From: Association between stopping renin-angiotensin system inhibitors immediately before hemodialysis initiation and subsequent cardiovascular events

 

Cases, n (%)

Rate, /100 PY

Hazard ratio (95% confidence interval)

Model 1

Model 2

Model 3

Mortality

 Continuing RASIs (n = 650)

150 (23%)

7.1

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Stopping RASIs (n = 67)

20 (30%)

8.9

1.25 (0.78–1.99)

1.23 (0.77–1.98)

0.82 (0.50–1.34)

Cardiovascular events

 Continuing RASIs (n = 650)

198 (30%)

10.9

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Stopping RASIs (n = 67)

30 (45%)

17.7

1.61 (1.10–2.37)

1.79 (1.22–2.64)

1.59 (1.06–2.38)

  1. Model 1: unadjusted; Model 2: adjusted for age, sex, body mass index, diabetes mellitus, and history of cardiovascular disease; Model 3: adjusted for Model 2 + creatinine, potassium, eGFR decline (the change in eGFR for 3 months before dialysis initiation), ion exchange resin, antiplatelet drugs, β-blockers, diuretics, and urgent dialysis
  2. PY person-years, RASIs renin-angiotensin system inhibitors, eGFR estimated glomerular filtration rate
Back to article page